These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34831458)

  • 1. Matrix Metalloproteinases Inhibition by Doxycycline Rescues Extracellular Matrix Organization and Partly Reverts Myofibroblast Differentiation in Hypermobile Ehlers-Danlos Syndrome Dermal Fibroblasts: A Potential Therapeutic Target?
    Chiarelli N; Zoppi N; Venturini M; Capitanio D; Gelfi C; Ritelli M; Colombi M
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermal fibroblast-to-myofibroblast transition sustained by αvß3 integrin-ILK-Snail1/Slug signaling is a common feature for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.
    Zoppi N; Chiarelli N; Binetti S; Ritelli M; Colombi M
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1010-1023. PubMed ID: 29309923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological insights in the pathogenesis of hypermobile Ehlers-Danlos syndrome from proteome profiling of patients' dermal myofibroblasts.
    Chiarelli N; Zoppi N; Ritelli M; Venturini M; Capitanio D; Gelfi C; Colombi M
    Biochim Biophys Acta Mol Basis Dis; 2021 Apr; 1867(4):166051. PubMed ID: 33383104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-Seq of Dermal Fibroblasts from Patients with Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders Supports Their Categorization as a Single Entity with Involvement of Extracellular Matrix Degrading and Proinflammatory Pathomechanisms.
    Ritelli M; Chiarelli N; Cinquina V; Zoppi N; Bertini V; Venturini M; Colombi M
    Cells; 2022 Dec; 11(24):. PubMed ID: 36552803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers‒Danlos Syndromes.
    Chiarelli N; Ritelli M; Zoppi N; Colombi M
    Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31409039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrastructure study of skin fibroblasts in patients with Ehlers-Danlos Syndrome (EDS): preliminary results.
    Celli M; Iacovino C; Febbo A; Lotti LV; Miraglia E; Celli L; Roberti V; Sernicola A; Zambrano A; Turchetti A; Vespa S; Giustini S
    Clin Ter; 2020; 171(5):e431-e436. PubMed ID: 32901788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes.
    Gensemer C; Burks R; Kautz S; Judge DP; Lavallee M; Norris RA
    Dev Dyn; 2021 Mar; 250(3):318-344. PubMed ID: 32629534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.
    Tinkle B; Castori M; Berglund B; Cohen H; Grahame R; Kazkaz H; Levy H
    Am J Med Genet C Semin Med Genet; 2017 Mar; 175(1):48-69. PubMed ID: 28145611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts.
    Zoppi N; Chiarelli N; Ritelli M; Colombi M
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical involvement of ZEB2 in collagen fibrillogenesis: the molecular similarity between Mowat-Wilson syndrome and Ehlers-Danlos syndrome.
    Teraishi M; Takaishi M; Nakajima K; Ikeda M; Higashi Y; Shimoda S; Asada Y; Hijikata A; Ohara O; Hiraki Y; Mizuno S; Fukada T; Furukawa T; Wakamatsu N; Sano S
    Sci Rep; 2017 Apr; 7():46565. PubMed ID: 28422173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal Symptoms in Marfan Syndrome and Hypermobile Ehlers-Danlos Syndrome.
    Inayet N; Hayat JO; Kaul A; Tome M; Child A; Poullis A
    Gastroenterol Res Pract; 2018; 2018():4854701. PubMed ID: 30151001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An acquired or heritable connective tissue disorder? A review of hypermobile Ehlers Danlos Syndrome.
    Martin A
    Eur J Med Genet; 2019 Jul; 62(7):103672. PubMed ID: 31102747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fascial thickness and stiffness in hypermobile Ehlers-Danlos syndrome.
    Wang TJ; Stecco A
    Am J Med Genet C Semin Med Genet; 2021 Dec; 187(4):446-452. PubMed ID: 34741592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin biopsy reveals generalized small fibre neuropathy in hypermobile Ehlers-Danlos syndromes.
    Igharo D; Thiel JC; Rolke R; Akkaya M; Weis J; Katona I; Schulz JB; Maier A
    Eur J Neurol; 2023 Mar; 30(3):719-728. PubMed ID: 36437696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermobility, the Ehlers-Danlos syndromes and chronic pain.
    Syx D; De Wandele I; Rombaut L; Malfait F
    Clin Exp Rheumatol; 2017; 35 Suppl 107(5):116-122. PubMed ID: 28967365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidisciplinary chronic pain management strategies in patients with Ehlers-Danlos syndromes.
    Gullapalli PA; Javed S
    Pain Manag; 2023 Jan; 13(1):5-14. PubMed ID: 36305215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtle differences in autonomic symptoms in people diagnosed with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.
    Martinez KL; Mauss C; Andrews J; Saboda K; Huynh JM; Sanoja AJ; Jesudas R; Byers PH; Laukaitis CM
    Am J Med Genet A; 2021 Jul; 185(7):2012-2025. PubMed ID: 33826221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing a self-management intervention to manage hypermobility spectrum disorders (HSD) and hypermobile Ehlers-Danlos syndrome (hEDS): an analysis informed by behaviour change theory.
    Bennett SE; Walsh N; Moss T; Palmer S
    Disabil Rehabil; 2022 Sep; 44(18):5231-5240. PubMed ID: 34101520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of pain and mobility disability in the hypermobile Ehlers-Danlos syndrome.
    Kalisch L; Hamonet C; Bourdon C; Montalescot L; de Cazotte C; Baeza-Velasco C
    Disabil Rehabil; 2020 Dec; 42(25):3679-3686. PubMed ID: 31060411
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.